Layilin is critical for mediating hyaluronan 35 kDa-induced intestinal epithelial tight junction protein ZO-1 in vitro and in vivo

• Published in: Matrix biology Vol. 66; pp. 93 - 109
• Main Authors: Kim, Yeojung, West, Gail A., Ray, Greeshma, Kessler, Sean P., Petrey, Aaron C., Fiocchi, Claudio, McDonald, Christine, Longworth, Michelle S., Nagy, Laura E., de la Motte, Carol A.
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier Science Ltd 01.03.2018
• Subjects: CD44 antigen; Colitis; Dextran; Dextran sulfate; Dietary supplements; Epithelium; Gene expression; Hyaluronic acid; Immunofluorescence; Inflammation; Inflammatory bowel disease; Inflammatory bowel diseases; Inflammatory diseases; Intestine; Laboratory animals; Organoids; Permeability; Proteins; Rodents; Sodium; Toll-like receptors; Zonula occludens-1 protein
• ISSN: 0945-053X; 1569-1802
• DOI: 10.1016/j.matbio.2017.09.003

Tight junction proteins are critical in maintaining homeostatic intestinal permeability. Multiple intestinal inflammatory diseases are correlated with reduced expression of tight junction proteins. We have recently reported that oral treatment of mice with Hyaluronan 35 kDa (HA35) increases colonic expression of tight junction protein zonula occludens-1 (ZO-1). Here, we investigate whether HA35 treatment enhances ZO-1 expression by direct interaction with intestinal epithelium in vitro and have identified the HA receptor responsible for HA35-mediated ZO-1 induction in colonic epithelium in vitro and in vivo. Our results reveal that HA35 treatment increases ZO-1 expression in mouse intestinal epithelial organoids, while large HA 2000 kDa is not internalized into the cells. Our immunofluorescence data indicate that layilin, but neither toll-like receptor-4 (TLR-4) nor CD44, mediate the HA35-induced ZO-1 expression in colonic epithelium in vitro and in vivo. Additionally, using layilin null mice we have determined that layilin mediates HA35 induction of ZO-1 in healthy mice and during dextran sulfate sodium (DSS)-induced colitis. Furthermore, we find that while ZO-1 expression levels are reduced, layilin expression levels are equivalent in inflammatory bowel disease (IBD) patients and non-IBD controls. Together, our data suggest that layilin is an important HA receptor, that mediates the effect of oral HA35 treatment on intestinal epithelium. HA35 holds promise as a simple dietary supplement to strengthen gut barrier defense.